<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230913221424&amp;utm_source=Chrome&amp;utm_medium=rss&amp; utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed -2<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230913221424&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 14 日星期四 02:14:28 +0000</lastbuilddate><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>心肌梗死后血流储备分数-阴性高风险斑块和临床结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37703036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在患有 MI 和 FFR 阴性非罪犯病变的患者中，高风险斑块的存在与较差的临床结果相关，这主要是由于计划外血运重建次数较多所致。尽管生理学引导的完全血运重建的事件发生率较低，但这些结果要求对含有高风险斑块的患者进行额外的药理学或局部治疗策略的研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 13 日。doi：10.1001/jamacardio.2023.2910。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：即使在血流储备分数 (FFR) 引导的完全血运重建之后，心肌梗死 (MI) 患者的主要心血管不良事件 (MACE) 复发率也很高。这些复发可能是由 FFR 阴性的高危非罪魁病变引起的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估光学相干断层扫描 (OCT) 识别的 FFR 阴性非罪犯病变高危斑块与 MI 患者 MACE 发生之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、背景和参与者：PECTUS-obs（在 STEMI [ST 段抬高 MI] 和 NSTEMI [非 STEMI] 后通过 OCT 识别残余非血流限制性病变患者中急性冠状动脉事件的危险因素）是一项国际性研究，多中心，前瞻性，观察性队列研究。在出现 MI 的患者中，对所有 FFR 阴性（FFR >; 0.80）非罪魁病变进行 OCT。高风险斑块的定义包含至少 2 个以下预先指定的标准：（1 ) 脂质弧至少 90°，(2) 纤维帽厚度小于 65 μm，以及 (3) 斑块破裂或存在血栓。患者入组时间为 2018 年 12 月 14 日至 2020 年 9 月 15 日。分析数据从2022年12月2日至2023年6月28日。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结局和衡量指标：比较有和没有高危斑块患者的 MACE（主要终点为全因死亡率、非致命性心梗或计划外血运重建的复合终点）2 年随访结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 438 名患者入组，其中 420 名患者的 OCT 结果可分析。纳入的患者中，平均 (SD) 年龄为 63 (10) 岁，其中 340 名 (81.0) 名男性，STEMI 和非 STEMI 的比例相同（217 [51.7%] 和 203 [48.3%]）。每名患者的平均 (SD) 为 1.17 (0.42) 个非罪魁病变。OCT 图像分析显示 143 名患者 (34.0%) 中至少有 1 个高风险斑块主要终点发生在 22 名存在高风险斑块的患者 (15.4%) 和 277 名不存在高风险斑块的患者中的 23 名 (8.3%) 中（风险比，1.93 [95% CI，1.08-3.47]；P = .02），主要是由于高危斑块患者中更多的计划外血运重建（143 例患者中的 14 例 [9.8%] vs 277 例患者中的 12 例 [4.3%]；P = .02）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在患有 MI 和 FFR 阴性非罪犯病变的患者中，高风险斑块的存在与较差的临床结果相关，这主要是由于计划外血运重建次数较多所致。尽管生理学引导的完全血运重建的事件发生率较低，但这些结果要求对含有高风险斑块的患者进行额外的药理学或局部治疗策略的研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37703036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37703036</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2910>10.1001/jamacardio.2023.2910</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37703036</guid><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><dc:creator>简-昆腾·莫尔</dc:creator><dc:creator>里克·HJA·沃勒伯格</dc:creator><dc:creator>阿努阿尔·贝尔卡塞米</dc:creator><dc:creator>雷尼库斯·赫尔曼尼德斯</dc:creator><dc:creator>马丁·莫维森</dc:creator><dc:creator>阿列克谢·普罗托波波夫</dc:creator><dc:creator>皮普·兰梅茨</dc:creator><dc:creator>奥列格·V·克雷斯佳尼诺夫</dc:creator><dc:creator>罗伯特·丹纳特</dc:creator><dc:creator>罗希特·M·奥姆劳辛</dc:creator><dc:creator>扬-彼得·范·奎克</dc:creator><dc:creator>卡琳·阿肯布特</dc:creator><dc:creator>德克·J·范德·海登</dc:creator><dc:creator>萨曼·拉苏尔</dc:creator><dc:creator>埃里克·利普西克</dc:creator><dc:creator>劳拉·罗德威尔</dc:creator><dc:creator>西里尔·科迈罗</dc:creator><dc:creator>彼得·达曼</dc:creator><dc:creator>托马斯·罗德尔</dc:creator><dc:creator>埃尔文·凯迪</dc:creator><dc:creator>马丁·A·范·列文</dc:creator><dc:creator>罗伯特·扬·范·格恩斯</dc:creator><dc:creator>尼尔斯·范·罗延</dc:creator><dc:date>2023-09-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>心肌梗死后血流储备分数-阴性高风险斑块和临床结果</dc:title><dc:identifier>下午：37703036</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2910</dc:identifier></item><item><title>院外心脏骤停后的长期生活质量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37703007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在这项调查研究的响应者中，超过 50% 的丹麦院外心脏骤停幸存者中，事件发生后 20 年内的长期健康相关生活质量一直很高且具有可比性这些发现支持资源分配和旨在提高院外心脏骤停后生存率的努力。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 13 日。doi：10.1001/jamacardio.2023.2934。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：分配资源以提高心脏骤停后的生存率需要幸存者拥有良好的生活质量，但缺乏长期数据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：确定 2001 年至 2019 年院外心脏骤停幸存者的生活质量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：本调查研究使用 EuroQol 健康问卷、12 项简短健康调查 (SF-12) 和医院焦虑和抑郁量表 (HADS) 来评估所有成年人的健康相关生活质量2001 年 6 月 1 日至 2019 年 8 月 31 日期间纳入丹麦心脏骤停登记处、2020 年 10 月仍存活的院外心脏骤停幸存者（随访期，0-1、>;1-2、>; 2-4、>;4-6、>;6-8、>;8-10、>;10-15 和 >;15-20 自被捕以来的年）。调查于 2020 年 10 月 1 日至 2021 年 5 月 31 日期间进行。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：所有经历过院外心脏骤停的患者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和测量方法：使用EuroQol健康问卷指数（EQ指数）评分和EQ视觉模拟量表测量自我报告的健康状况，使用SF-12测量身心健康，使用HADS测量焦虑和抑郁。使用描述性统计进行分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 4545 名幸存者中，2552 名 (56.1%) 完成了调查，自事件发生以来的中位随访时间为 5.5 年（IQR，2.9-8.9 年）。响应者和非响应者的年龄相当（中位 [IQR]，67 [58-74] 岁 vs 68 [56-78] 岁），2075 名应答者 (81.3%) 为男性，477 名 (18.7%) 为女性（对比 1473 名男性 [73.9%] 和 520 名女性 [26.1%] 无应答者）。对于最短随访（0-1年）和最长随访（>;15-20年）组，EQ指数中位数分别为0.9（IQR，0.7-1.0）和0.9（0.8-1.0）。对于所有响应者，平均 (SD) SF-12 身体健康评分为 43.3 (12.3)，SF-12 心理健康评分为 52.9 (8.3)。所有 3 个评分与一般丹麦参考人群相当。根据 HADS 评分， 73.0%（74 人中的 54 人）的 0 至 1 年幸存者报告焦虑风险较低，而 15 至 20 年幸存者中这一比例为 89.3%（112 人中的 100 人）；对于抑郁症状，这些比例为分别为 79.7% (n = 59) 和 87.5% (n = 98)。在所有随访期间，幸存者群体的健康相关生活质量相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项调查研究的响应者中，超过 50% 的丹麦院外心脏骤停幸存者中，事件发生后 20 年内的长期健康相关生活质量一直很高且具有可比性这些发现支持资源分配和旨在提高院外心脏骤停后生存率的努力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37703007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37703007</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2934>10.1001/jamacardio.2023.2934</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37703007</guid><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><dc:creator>哈曼·约尼斯</dc:creator><dc:creator>凯瑟琳·科尔德·索伦森</dc:creator><dc:creator>亨里克·博吉尔德</dc:creator><dc:creator>克里斯蒂安·邦德加德·林格伦</dc:creator><dc:creator>卡罗莱纳州马耳他汉森</dc:creator><dc:creator>克里斯托弗·B·格兰杰</dc:creator><dc:creator>弗雷德里克·福克</dc:creator><dc:creator>海勒·克拉茨·克里斯滕森</dc:creator><dc:creator>布丽塔·詹森</dc:creator><dc:creator>米克尔·波斯堡·安德森</dc:creator><dc:creator>维琪·L·乔希</dc:creator><dc:creator>安-多尔特·兹维斯勒</dc:creator><dc:creator>克里斯蒂安·托普·佩德森</dc:creator><dc:creator>克里斯蒂安·克拉格霍尔姆</dc:creator><dc:date>2023-09-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>院外心脏骤停后的长期生活质量</dc:title><dc:identifier>下午：37703007</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2934</dc:identifier></item><item><title> Evinacumab 对难治性高胆固醇血症患者的长期疗效和安全性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37703006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在难治性高胆固醇血症患者中，evinacumab 可持续降低 LDL-C 水平，并且总体耐受性良好。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 13 日。doi：10.1001/jamacardio.2023.2921。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：尽管采用最大耐受的降脂疗法 (LLT) 组合治疗，但仍未达到指南定义的低密度脂蛋白胆固醇 (LDL-C) 阈值的难治性高胆固醇血症患者，患动脉粥样硬化性心血管疾病 (ASCVD) 的风险增加。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估 evinacumab 对难治性高胆固醇血症患者的长期疗效和安全性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这项随机临床试验包括为期 2 周的筛选期，随后是为期 16 周的皮下注射方案双盲治疗期 (DBTP)（evinacumab，450 mg，每周一次 [QW]；evinacumab，300 mg，每周一次；evinacumab，300 mg，每 2 周一次；或安慰剂 QW）或 24 周 DBTP 静脉注射方案（evinacumab，15 mg/kg，每 4 周一次 [Q4W]；evinacumab，5 mg/kg，Q4W；evinacumab，5 mg/kg，每 4 周一次；或安慰剂 Q4W）；仅用于静脉治疗的 48 周开放标签治疗期（OLTP）；以及 24 周的随访期。该研究招募了来自 20 个国家 85 个地点的患者；原发性高胆固醇血症患者（进入 48 周 OLTP 的患者（定义为杂合子家族性高胆固醇血症或既定的临床 ASCVD（无家族性高胆固醇血症））也被纳入其中。此外，患者的高胆固醇血症对于最大耐受 LLT 是难治性的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预措施：所有进入 OLTP 的患者均接受 evinacumab，15 mg/kg，每季度静脉注射。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：疗效结果包括 LDL-C 水平和其他脂质/脂蛋白参数从基线到第 72 周（OLTP 结束）的变化。安全性结果包括治疗中出现的不良事件 (TEAE) 的评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 96 名患者（平均 [SD] 年龄，54.4 [11.3] 岁；52 名女性 [54.2%]）进入 OLTP，其中 88 名 (91.7%) 完成了 OLTP。平均 (SD) 基线 LDL-C水平为 145.9 (55.2) mg/dL。第 72 周时，evinacumab，15 mg/kg，整个队列中的平均 (SD) LDL-C 水平较基线降低了 45.5% (28.7%)。Evinacumab，15 mg/kg ，降低平均 (SD) 载脂蛋白 B (38.0% [22.1%])、非高密度脂蛋白胆固醇 (48.4% [23.2%])、总胆固醇 (42.6% [17.5%]) 和中位 (IQR) 空腹甘油三酯(57.2% [65.4%-44.4%]) 在整个队列中第 72 周时的水平与基线相比。96 名患者中有 78 名 (81.3%) 发生了 TEAE。96 名患者中有 9 名 (9.4%) 发生了严重的 TEAE；所有患者均被考虑与研究治疗无关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在难治性高胆固醇血症患者中，evinacumab 可持续降低 LDL-C 水平，并且总体耐受性良好。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT03175367。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37703006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37703006</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2921>10.1001/jamacardio.2023.2921</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37703006</guid><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><dc:creator>罗伯特·S·罗森森</dc:creator><dc:creator>莱斯利·J·伯吉斯</dc:creator><dc:creator>克里斯托夫·F·埃本比希勒</dc:creator><dc:creator>塞思·J·鲍姆</dc:creator><dc:creator>埃里克·SG·斯特罗斯</dc:creator><dc:creator>沙齐亚·阿里</dc:creator><dc:creator>纳格瓦·基拉</dc:creator><dc:creator>詹妮弗·麦金尼斯</dc:creator><dc:creator>丹尼尔·高德</dc:creator><dc:creator>罗伯特·波迪</dc:creator><dc:date>2023-09-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>Evinacumab 对难治性高胆固醇血症患者的长期疗效和安全性</dc:title><dc:identifier>下午：37703006</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2921</dc:identifier></item><item><title>图中错误</title><link/>https://pubmed.ncbi.nlm.nih.gov/37702722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 1 日；8(9):891。doi: 10.1001/jamacardio.2023.3311。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37702722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37702722</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3311>10.1001/jamacardio.2023.3311</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37702722</guid><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><dc:date> 2023-09-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>图中错误</dc:title><dc:identifier>下午：37702722</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3311</dc:identifier></item><item><title>美国医学会杂志心脏病学</title><link/>https://pubmed.ncbi.nlm.nih.gov/37702721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 1 日；8(9):802。doi: 10.1001/jamacardio.2022.3452。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37702721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37702721</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2022.3452>10.1001/jamacardio.2022.3452</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37702721</guid><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><dc:date> 2023-09-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>美国医学会杂志心脏病学</dc:title><dc:identifier>下午：37702721</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2022.3452</dc:identifier></item><item><title>心脏磁共振生物标志物作为心肌疾病心血管试验的替代终点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37700499/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>心脏磁共振在心肌疾病患者的诊断、风险分层和管理方面提供了多个方面。特别是，其精确监测疾病活动的功能有助于量化对新疗法的反应。这篇综述批判性地评价了心脏磁共振成像的价值生物标志物作为前瞻性临床试验的替代终点。主要重点是全面概述已建立的心脏磁的价值... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 13:ehad510.doi: 10.1093/eurheartj/ehad510. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心脏磁共振在心肌疾病患者的诊断、风险分层和管理方面提供了多个方面。特别是，其精确监测疾病活动的功能有助于量化对新疗法的反应。这篇综述批判性地评价了心脏磁共振成像的价值生物标志物作为前瞻性临床试验的替代终点。主要重点是全面概述已确定的心脏磁共振参数在心肌疾病中的价值。这些疾病包括心力衰竭、心脏淀粉样变性、铁过载心肌病、肥厚性心肌病、心脏肿瘤和炎症性心肌病如心肌炎和结节病。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37700499/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37700499</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad510>10.1093/eurheartj/ehad510</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37700499</guid><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><dc:creator>多米尼克·本茨</dc:creator><dc:creator>克里斯托夫·格拉尼</dc:creator><dc:creator>帕纳吉奥蒂斯·安提奥克斯</dc:creator><dc:creator>博巴克·海达里</dc:creator><dc:creator>马克·科林·吉斯勒</dc:creator><dc:creator>银阁</dc:creator><dc:creator>萨拉·AM·卡迪</dc:creator><dc:creator>莎米拉·多巴拉</dc:creator><dc:creator>邝伟文</dc:creator><dc:date>2023-09-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心脏磁共振生物标志物作为心肌疾病心血管试验的替代终点</dc:title><dc:identifier>下午:37700499</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad510</dc:identifier></item><item><title>对具有免疫特征的基质细胞控制的早期妊娠的时空洞察</title><link/>https://pubmed.ncbi.nlm.nih.gov/37699390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>连接胚胎着床和胎盘的子宫内膜蜕膜化是短暂的，但对于成功妊娠至关重要，然而，这一点尚未得到系统研究。在这里，我们使用 scStereo-seq 技术来空间可视化和定义由不同的免疫、内皮、早期妊娠小鼠的滋养层细胞和蜕膜基质细胞 (DSC)。我们解开了 DSC 转分化轨迹，并令人惊讶地发现了一种双重功能…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 7 日：S0092-8674(23)00909-1. doi: 10.1016/j.cell.2023.08.020. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">连接胚胎着床和胎盘的子宫内膜蜕膜化是短暂的，但对于成功妊娠至关重要，然而，这一点尚未得到系统研究。在这里，我们使用 scStereo-seq 技术来空间可视化和定义由不同的免疫、内皮、早期妊娠小鼠的滋养层细胞和蜕膜基质细胞 (DSC)。我们解开了 DSC 转分化轨迹，并令人惊讶地发现了一种具有双重功能的免疫特征 DSC (iDSC)。我们发现，未成熟的 DSC 会吸引免疫细胞并诱导蜕膜血管生成蜕膜化起始期间的间充质-上皮过渡枢纽。iDSC 能够招募和抑制免疫细胞、控制血管形成并分别促进免疫细胞组装和血管枢纽处的细胞溶解，以在后期建立蜕膜稳态。导致免疫细胞异常积累血管中枢，它破坏了蜕膜中枢的规范，并最终导致 DBA/2 交配的 CBA/J 小鼠妊娠并发症。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37699390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37699390</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.020>10.1016/j.cell.2023.08.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37699390</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator>杨敏</dc:creator><dc:creator>王珍妮</dc:creator><dc:creator>孟凡举</dc:creator><dc:creator>张飞翔</dc:creator><dc:creator>沉慧</dc:creator><dc:creator>克斯汀·基特</dc:creator><dc:creator>刘腾飞</dc:creator><dc:creator>韦涛</dc:creator><dc:creator>杜鹏</dc:creator><dc:date>2023-09-12</dc:date><dc:source>细胞</dc:source><dc:title>对具有免疫特征的基质细胞控制的早期妊娠的时空洞察</dc:title><dc:identifier>下午:37699390</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.020</dc:identifier></item><item><title> SPHK2/S1P 轴改变平滑肌细胞组蛋白乙酰基可促进肺动脉高压</title><link/>https://pubmed.ncbi.nlm.nih.gov/37698017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>结论：人肺动脉平滑肌细胞中 SPHK2 的表达及其对可逆组蛋白 H3K9 乙酰化的激活代表了可以减轻 PH 血管重塑的新治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 12 日。doi：10.1161/CIRCRESAHA.123.322740。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：对肺动脉高压 (PH) 血管重塑的表观遗传调控知之甚少。转录调节、组蛋白乙酰化密码改变染色质可及性以促进转录激活。我们的目标是确定破坏 PH 中表观遗传平衡的上游机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：人肺动脉平滑肌细胞 (PASMC)、人特发性肺动脉高压 (iPAH)：人 PASMC、iPAH 肺组织、衰竭供体肺组织、人肺微血管内皮细胞、iPAH:PASMC 和非 iPAH:PASMC RNA-利用 seq 数据库、NanoString nCounter 以及使用核酸酶进行靶标切割和释放来研究组蛋白乙酰化、超乙酰化靶标、蛋白质和基因表达、鞘脂激活、细胞增殖和基因靶标识别。SPHK2（鞘氨醇激酶 2）敲除与缺氧 3 周后对照 C57BL/6NJ 小鼠并评估 PH 指数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现人类 PASMC 易受转录促进表观遗传介质组蛋白乙酰化的影响，导致转录机制发生改变，并证实其在 PH:PASMC 细胞中的病理存在。我们报告 SPHK2 在 iPAH 肺中升高高达 20 倍在 PH 发病过程中，核 SPHK2 激活核生物活性脂质 S1P（1-磷酸鞘氨醇）催化酶，并通过 EMAP 介导转录调节组蛋白 H3K9 乙酰化（乙酰组蛋白 H3 赖氨酸 9 [Ac-H3K9]） （内皮单核细胞激活多肽） II. 在 iPAH 肺中，我们发现可逆表观遗传转录调节剂 Ac-H3K9:H3 的比例升高了 4 倍。SPHK2 的缺失抑制了小鼠缺氧诱导的 PH 和 Ac-H3K9。我们发现肺血管内皮细胞是 EMAP II/SPHK2/S1P 轴的启动因子，通过组蛋白 H3K9 的高度乙酰化，改变具有 PASMC 特异性的乙酰组。利用靶标下的切割并使用核酸酶释放，我们进一步表明 EMAP II 介导的SPHK2 有潜力通过超乙酰化 KLF4 顺式调节元件来修饰多能性因子 KLF4（Krüppel 样因子 4）的局部转录机制，而 SPHK2 的删除和靶向抑制则可以挽救改变转录的 Ac-H3K9。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：人肺动脉平滑肌细胞中 SPHK2 的表达及其对可逆组蛋白 H3K9 乙酰化的激活代表了可以减轻 PH 血管重塑的新治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37698017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37698017</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322740>10.1161/CIRCRESAHA.123.322740</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37698017</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator> A 杜沙尼 CU 拉纳辛哈</dc:creator><dc:creator>玛吉·霍洛汉</dc:creator><dc:creator>卡林·博格</dc:creator><dc:creator>黛博拉·多纳休</dc:creator><dc:creator>拉斐尔·D·库克</dc:creator><dc:creator>马丁·格里格</dc:creator><dc:creator>安德鲁·金</dc:creator><dc:creator>维多利亚·普罗普利斯</dc:creator><dc:creator>弗朗西斯·卡斯特利诺</dc:creator><dc:creator>玛格丽特·施瓦茨</dc:creator><dc:date>2023-09-12</dc:date><dc:source>流通研究</dc:source><dc:title>SPHK2/S1P 轴改变平滑肌细胞组蛋白乙酰基可促进肺动脉高压</dc:title><dc:identifier>下午：37698017</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322740</dc:identifier></item><item><title>实施预防科学以消除医疗保健不平等，实现心血管健康：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37698007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>预防心血管及相关疾病是实现理想心血管健康以改善个人和社区整体健康和福祉的基础。健康的社会决定因素和医疗保健不平等会对理想的心血管健康和疾病预防产生不利影响。有效和公平的方式需要协调的多学科和多层次的方法。在这份科学声明中，我们研究...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 12 日。doi：10.1161/CIR.0000000000001171。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">预防心血管及相关疾病是实现理想心血管健康以改善个人和社区整体健康和福祉的基础。健康的社会决定因素和医疗保健不平等会对理想的心血管健康和疾病预防产生不利影响。有效和公平的方式需要协调的多学科和多层次方法。在这份科学声明中，我们在利用现有资源减少医疗保健不平等并优化预防性心血管护理服务的背景下，研究了实现理想心血管健康及其相关状况的障碍我们主要讨论（1）涉及直接患者护理的跨医疗保健环境的干预措施，（2）利用医疗保健技术，（3）优化多专业/多专业合作和干预措施，（4）吸引当地社区，以及（5）改善社区。通过与健康相关的政府政策来改善环境，所有这些政策的重点都是使所有人都享有公平的理想心血管健康。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37698007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37698007</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001171>10.1161/CIR.0000000000001171</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37698007</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator>阿南迪塔·阿加瓦拉</dc:creator><dc:creator>贾迪普·帕特尔</dc:creator><dc:creator>詹娜·斯蒂芬斯</dc:creator><dc:creator>沙马里尔·罗伯森</dc:creator><dc:creator>朱厄尔·斯科特</dc:creator><dc:creator>特里萨·贝基</dc:creator><dc:creator>伊丽莎白·杰克逊</dc:creator><dc:creator>美国心脏协会预防科学委员会、流行病学和预防委员会、心血管和中风护理委员会、临床心脏病学委员会、生活方式和心脏代谢健康委员会、周围血管疾病委员会、护理质量和结果研究委员会以及中风理事会</dc:creator><dc:date>2023-09-12</dc:date><dc:source>循环</dc:source><dc:title>实施预防科学以消除医疗保健不平等，实现心血管健康：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37698007</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001171</dc:identifier></item><item><title>导管消融可改善 AF 和终末期 HF 患者的预后</title><link/>https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 11 日。doi：10.1038/s41569-023-00932-9。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37697073</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00932-9>10.1038/s41569-023-00932-9</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37697073</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>卡琳娜·黄</dc:creator><dc:date>2023-09-11</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>导管消融可改善 AF 和终末期 HF 患者的预后</dc:title><dc:identifier>下午:37697073</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00932-9</dc:identifier></item><item><title>梗死重塑中的心脏周细胞多样性：不仅仅是血管支持细胞？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):899-902. doi: 10.1161/CIRCULATIONAHA.123.065676. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37695834</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065676>10.1161/CIRCULATIONAHA.123.065676</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695834</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>托马斯·摩尔-莫里斯</dc:creator><dc:creator>西尔维娅·M·埃文斯</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>梗死重塑中的心脏周细胞多样性：不仅仅是血管支持细胞？</dc:title><dc:identifier>下午:37695834</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065676</dc:identifier></item><item><title> Cosentino 和 Marino 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环刺突蛋白”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):906-907. doi: 10.1161/CIRCULATIONAHA.123.064000. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37695833</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064000>10.1161 / CIRCULATIONAHA.123.064000</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695833</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>马可·科森蒂诺</dc:creator><dc:creator>弗兰卡·马里诺</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Cosentino 和 Marino 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环刺突蛋白”的信函</dc:title><dc:identifier>下午:37695833</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064000</dc:identifier></item><item><title>血管内成像引导下经皮冠状动脉介入治疗对慢性完全闭塞的预后影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):903-905. doi: 10.1161/CIRCULATIONAHA.123.065876. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37695832</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065876>10.1161 / CIRCULATIONAHA.123.065876</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695832</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>洪大卫</dc:creator><dc:creator>金尚民</dc:creator><dc:creator>李相耀</dc:creator><dc:creator>崔基洪</dc:creator><dc:creator>宋永斌</dc:creator><dc:creator>李正英</dc:creator><dc:creator>李承宰</dc:creator><dc:creator>尹庆浩</dc:creator><dc:creator>赵在英</dc:creator><dc:creator>金灿俊</dc:creator><dc:creator>安孝淑</dc:creator><dc:creator>南昌旭</dc:creator><dc:creator>尹赫俊</dc:creator><dc:creator>朴容焕</dc:creator><dc:creator>王秀利</dc:creator><dc:creator>郑振玉</dc:creator><dc:creator>宋必相</dc:creator><dc:creator>都俊亨</dc:creator><dc:creator>赵尚浩</dc:creator><dc:creator>尹昌焕</dc:creator><dc:creator>姜敏奎</dc:creator><dc:creator>许真仙</dc:creator><dc:creator>李宽勇</dc:creator><dc:creator>林英孝</dc:creator><dc:creator>赵润亨</dc:creator><dc:creator>赵镇万</dc:creator><dc:creator>张宇振</dc:creator><dc:creator>千国镇</dc:creator><dc:creator>朴泽圭</dc:creator><dc:creator>杨正勋</dc:creator><dc:creator>崔胜赫</dc:creator><dc:creator>权贤哲</dc:creator><dc:creator>韩柱容</dc:creator><dc:creator>李柱明</dc:creator><dc:creator>翻新综合体 PCI 调查员</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>血管内成像引导下经皮冠状动脉介入治疗对慢性完全闭塞的预后影响</dc:title><dc:identifier>下午:37695832</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065876</dc:identifier></item><item><title>为什么预防心脏病学的新疗法可能面临马拉松而不是短跑</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):859-861. doi: 10.1161/CIRCULATIONAHA.122.063099. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37695831</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063099>10.1161/CIRCULATIONAHA.122.063099</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695831</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乔安娜·卡瓦利尔</dc:creator><dc:creator>尼尚·P·沙阿</dc:creator><dc:creator>迈克尔·A·炽热</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>为什么预防心脏病学的新疗法可能面临马拉松而不是短跑</dc:title><dc:identifier>下午:37695831</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063099</dc:identifier></item><item><title> Schwartz 和 Prasad 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):908-909. doi: 10.1161/CIRCULATIONAHA.123.064414. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37695830</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064414>10.1161/CIRCULATIONAHA.123.064414</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695830</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·大卫·施瓦茨</dc:creator><dc:creator>卡姆拉·K·普拉萨德</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Schwartz 和 Prasad 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信函</dc:title><dc:identifier>下午:37695830</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064414</dc:identifier></item><item><title> Yonker 等人对有关文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信件的回复</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):910-911. doi: 10.1161/CIRCULATIONAHA.123.065629. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37695829</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065629>10.1161/CIRCULATIONAHA.123.065629</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695829</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>莱尔·M·扬克</dc:creator><dc:creator>阿莱西奥·法萨诺</dc:creator><dc:creator>大卫·R·沃尔特</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Yonker 等人对有关文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信件的回复</dc:title><dc:identifier>下午:37695829</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065629</dc:identifier></item><item><title>通过血脑屏障的荷尔蒙把关控制着蚂蚁的种姓特定行为</title><link/>https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913221424&amp;v=2.17.9.post6+86293ac<description>在这里，我们揭示了血脑屏障 (BBB) 在调节蚂蚁复杂的社会行为中发挥的意想不到的作用。利用 scRNA-seq，我们发现了一种称为保幼激素酯酶 (Jhe) 的关键激素降解酶位于 BBB 中。 ），我们表明这种定位控制着进入大脑的保幼激素（JH3）的水平。Jhe水平的操纵会重新编程蚂蚁种姓之间的大脑转录组。虽然蚂蚁Jhe被保留并在BBB内的细胞内发挥作用，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 24 日：S0092-8674(23)00856-5. doi: 10.1016/j.cell.2023.08.002. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Here, we reveal an unanticipated role of the blood-brain barrier (BBB) in regulating complex social behavior in ants. Using scRNA-seq, we find localization in the BBB of a key hormone-degrading enzyme called juvenile hormone esterase (Jhe), and we show that this localization governs the level of juvenile hormone (JH3) entering the brain. Manipulation of the Jhe level reprograms the brain transcriptome between ant castes. Although ant Jhe is retained and functions intracellularly within the BBB, we show that Drosophila Jhe is naturally extracellular. Heterologous expression of ant Jhe into the Drosophila BBB alters behavior in fly to mimic what is seen in ants. Most strikingly, manipulation of Jhe levels in ants reprograms complex behavior between worker castes. Our study thus uncovers a remarkable, potentially conserved role of the BBB serving as a molecular gatekeeper for a neurohormonal pathway that regulates social behavior.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37683635</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.002>10.1016/j.cell.2023.08.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37683635</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Linyang Ju</dc:creator><dc:creator> Karl M Glastad</dc:creator><dc:creator> Lihong Sheng</dc:creator><dc:creator> Janko Gospocic</dc:creator><dc:creator> Callum J Kingwell</dc:creator><dc:creator> Shawn M Davidson</dc:creator><dc:creator> Sarah D Kocher</dc:creator><dc:creator> Roberto Bonasio</dc:creator><dc:creator> Shelley L Berger</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Cell</dc:source><dc:title> Hormonal gatekeeping via the blood-brain barrier governs caste-specific behavior in ants</dc:title><dc:identifier> pmid:37683635</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.002</dc:identifier></item><item><title> Genetic manipulation of Patescibacteria provides mechanistic insights into microbial dark matter and the epibiotic lifestyle</title><link/> https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913221424&amp;v=2.17.9.post6+86293ac<description> Patescibacteria, also known as the candidate phyla radiation (CPR), are a diverse group of bacteria that constitute a disproportionately large fraction of microbial dark matter. Its few cultivated members, belonging mostly to Saccharibacteria, grow as epibionts on host Actinobacteria. Due to a lack of suitable tools, the genetic basis of this lifestyle and other unique features of Patescibacteira remain unexplored. Here, we show that Saccharibacteria exhibit natural competence, and we exploit... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 30:S0092-8674(23)00906-6. doi: 10.1016/j.cell.2023.08.017. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Patescibacteria, also known as the candidate phyla radiation (CPR), are a diverse group of bacteria that constitute a disproportionately large fraction of microbial dark matter. Its few cultivated members, belonging mostly to Saccharibacteria, grow as epibionts on host Actinobacteria. Due to a lack of suitable tools, the genetic basis of this lifestyle and other unique features of Patescibacteira remain unexplored. Here, we show that Saccharibacteria exhibit natural competence, and we exploit this property for their genetic manipulation. Imaging of fluorescent protein-labeled Saccharibacteria provides high spatiotemporal resolution of phenomena accompanying epibiotic growth, and a transposon-insertion sequencing (Tn-seq) genome-wide screen reveals the contribution of enigmatic Saccharibacterial genes to growth on their hosts. Finally, we leverage metagenomic data to provide cutting-edge protein structure-based bioinformatic resources that support the strain Southlakia epibionticum and its corresponding host, Actinomyces israelii, as a model system for unlocking the molecular underpinnings of the epibiotic lifestyle.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37683634</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.017>10.1016/j.cell.2023.08.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37683634</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Yaxi Wang</dc:creator><dc:creator> Larry A Gallagher</dc:creator><dc:creator> Pia A Andrade</dc:creator><dc:creator> Andi Liu</dc:creator><dc:creator> Ian R Humphreys</dc:creator><dc:creator> Serdar Turkarslan</dc:creator><dc:creator> Kevin J Cutler</dc:creator><dc:creator> Mario L Arrieta-Ortiz</dc:creator><dc:creator> Yaqiao Li</dc:creator><dc:creator> Matthew C Radey</dc:creator><dc:creator> Jeffrey S McLean</dc:creator><dc:creator> Qian Cong</dc:creator><dc:creator> David Baker</dc:creator><dc:creator> Nitin S Baliga</dc:creator><dc:creator> S Brook Peterson</dc:creator><dc:creator> Joseph D Mougous</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Cell</dc:source><dc:title> Genetic manipulation of Patescibacteria provides mechanistic insights into microbial dark matter and the epibiotic lifestyle</dc:title><dc:identifier> pmid:37683634</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.017</dc:identifier></item><item><title> Epoxyeicosatrienoic Acids Prevent Cardiac Dysfunction in Viral Myocarditis via IFN-I Signaling</title><link/> https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913221424&amp;v=2.17.9.post6+86293ac<description> Myocarditis is a challenging inflammatory disease of the heart, and better understanding of its pathogenesis is needed to develop specific drug therapies. Epoxyeicosatrienoic acids (EETs), active molecules synthesized by CYP (cytochrome P450) enzymes from arachidonic acids and hydrolyzed to less active dihydroxyeicosatrienoic acids by sEH (soluble epoxide hydrolase), have been attributed anti-inflammatory activity. Here, we investigated whether EETs have immunomodulatory activity and exert... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Sep 8. doi: 10.1161/CIRCRESAHA.123.322619. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Myocarditis is a challenging inflammatory disease of the heart, and better understanding of its pathogenesis is needed to develop specific drug therapies. Epoxyeicosatrienoic acids (EETs), active molecules synthesized by CYP (cytochrome P450) enzymes from arachidonic acids and hydrolyzed to less active dihydroxyeicosatrienoic acids by sEH (soluble epoxide hydrolase), have been attributed anti-inflammatory activity. Here, we investigated whether EETs have immunomodulatory activity and exert protective effects on coxsackie B3 virus-induced myocarditis. Viral infection altered eicosanoid epoxide and diol levels in both patients with myocarditis and in the murine heart and correlated with the increased expression and activity of sEH after coxsackie B3 virus infection. Administration of a sEH inhibitor prevented coxsackie B3 virus-induced cardiac dysfunction and inflammatory infiltration. Importantly, EET/sEH inhibitor treatment attenuated viral infection or improved viral resistance by activating type I IFN (interferon) signaling. At the molecular level, EETs enhanced the interaction between GSK3β (glycogen synthase kinase-3 beta) and TBK1 (TANK-binding kinase 1) to promote IFN-β production. Our findings revealed that EETs and sEH inhibitors prevent the progress of coxsackie B3 virus-induced myocarditis, particularly by promoting viral resistance by increasing IFN production.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37681352</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322619>10.1161/CIRCRESAHA.123.322619</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681352</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Zhou Zhou</dc:creator><dc:creator> Min Zhang</dc:creator><dc:creator> Chengcheng Zhao</dc:creator><dc:creator> Xu Gao</dc:creator><dc:creator> Zheng Wen</dc:creator><dc:creator> Junfang Wu</dc:creator><dc:creator> Chen Chen</dc:creator><dc:creator> Ingrid Fleming</dc:creator><dc:creator> Jiong Hu</dc:creator><dc:creator> Dao Wen Wang</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation research</dc:source><dc:title> Epoxyeicosatrienoic Acids Prevent Cardiac Dysfunction in Viral Myocarditis via IFN-I Signaling</dc:title><dc:identifier> pmid:37681352</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322619</dc:identifier></item><item><title> Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913221424&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.065614. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are inconsistent between the US Food and Drug Administration and European Medicines Agency for patients with atrial fibrillation. Optimal apixaban dosing in chronic kidney disease remains unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: With the use of deidentified electronic health record data from the Optum Labs Data Warehouse, patients with atrial fibrillation and chronic kidney disease stage 4/5 initiating apixaban between 2013 and 2021 were identified. Risks of bleeding and stroke/systemic embolism were compared by apixaban dose (5 versus 2.5 mg), adjusted for baseline characteristics by the inverse probability of treatment weighting. The Fine-Gray subdistribution hazard model was used to account for the competing risk of death. Cox regression was used to examine risk of death by apixaban dose. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 4313 apixaban new users, 1705 (40%) received 5 mg and 2608 (60%) received 2.5 mg. Patients treated with 5 mg apixaban were younger (mean age, 72 versus 80 years), with greater weight (95 versus 80 kg) and higher serum creatinine (2.7 versus 2.5 mg/dL). Mean estimated glomerular filtration rate was not different between the groups (24 versus 24 mL·min <sup>-1</sup> ·1.73 m <sup>-2</sup> ). In inverse probability of treatment weighting analysis, apixaban 5 mg was associated with a higher risk of bleeding (incidence rate 4.9 versus 2.9 events per 100 person-years; incidence rate difference, 2.0 [95% CI, 0.6-3.4] events per 100 person-years; subdistribution hazard ratio, 1.63 [95% CI, 1.04-2.54]). There was no difference between apixaban 5 mg and 2.5 mg groups in the risk of stroke/systemic embolism (3.3 versus 3.0 events per 100 person-years; incidence rate difference, 0.2 [95% CI, -1.0 to 1.4] events per 100 person-years; subdistribution hazard ratio, 1.01 [95% CI, 0.59-1.73]), or death (9.9 versus 9.4 events per 100 person-years; incidence rate difference, 0.5 [95% CI, -1.6 to 2.6] events per 100 person-years; hazard ratio, 1.03 [95% CI, 0.77-1.38]). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37681341</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065614>10.1161/CIRCULATIONAHA.123.065614</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681341</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Yunwen Xu</dc:creator><dc:creator> Alex R Chang</dc:creator><dc:creator> Lesley A Inker</dc:creator><dc:creator> Mara McAdams-DeMarco</dc:creator><dc:creator> Morgan E Grams</dc:creator><dc:creator> Jung-Im Shin</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation</dc:source><dc:title> Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease</dc:title><dc:identifier> pmid:37681341</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065614</dc:identifier></item><item><title> Changes in Cardiovascular Spending, Care Utilization, and Clinical Outcomes Associated With Participation in Bundled Payments for Care Improvement Advanced</title><link/> https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913221424&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Participation in BPCI-A was not associated with spending reductions, changes in care use, or quality improvements for the cardiovascular medical events or procedures offered in the model. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.065109. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Bundled Payments for Care Improvement Advanced (BPCI-A) is a Medicare initiative that aims to incentivize reductions in spending for episodes of care that start with a hospitalization and end 90 days after discharge. Cardiovascular disease, an important driver of Medicare spending, is one of the areas of focus BPCI-A. It is unknown whether BPCI-A is associated with spending reductions or quality improvements for the 3 cardiovascular medical events or 5 cardiovascular procedures in the model. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In this retrospective cohort study, we conducted difference-in-differences analyses using Medicare claims for patients discharged between January 1, 2017, and September 30, 2019, to assess differences between BPCI-A hospitals and matched nonparticipating control hospitals. Our primary outcomes were the differential changes in spending, before versus after implementation of BPCI-A, for cardiac medical and procedural conditions at BPCI-A hospitals compared with controls. Secondary outcomes included changes in patient complexity, care use, healthy days at home, readmissions, and mortality. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Baseline spending for cardiac medical episodes at BPCI-A hospitals was $25 606. The differential change in spending for cardiac medical episodes at BPCI-A versus control hospitals was $16 (95% CI, -$228 to $261; <i>P</i> =0.90). Baseline spending for cardiac procedural episodes at BPCI-A hospitals was $37 961. The differential change in spending for cardiac procedural episodes was $171 (95% CI, -$429 to $772; <i>P</i> =0.58). There were minimal differential changes in physicians&#39; care patterns such as the complexity of treated patients or in their care use. At BPCI-A versus control hospitals, there were no significant differential changes in rates of 90-day readmissions (differential change, 0.27% [95% CI, -0.25% to 0.80%] for medical episodes; differential change, 0.31% [95% CI, -0.98% to 1.60%] for procedural episodes) or mortality (differential change, -0.14% [95% CI, -0.50% to 0.23%] for medical episodes; differential change, -0.36% [95% CI, -1.25% to 0.54%] for procedural episodes). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Participation in BPCI-A was not associated with spending reductions, changes in care use, or quality improvements for the cardiovascular medical events or procedures offered in the model.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913221424&v=2.17.9.post6+86293ac">37681315</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065109>10.1161/CIRCULATIONAHA.123.065109</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681315</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Sukruth A Shashikumar</dc:creator><dc:creator> Jie Zheng</dc:creator><dc:creator> E John Orav</dc:creator><dc:creator> Arnold M Epstein</dc:creator><dc:creator> Karen E Joynt Maddox</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation</dc:source><dc:title> Changes in Cardiovascular Spending, Care Utilization, and Clinical Outcomes Associated With Participation in Bundled Payments for Care Improvement Advanced</dc:title><dc:identifier> pmid:37681315</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065109</dc:identifier></item></channel></rss>